NCT00253370View on ClinicalTrials.gov

Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

May 31, 2008

Study Completion Date

September 30, 2010

Conditions
Adenocarcinoma of the Gastroesophageal JunctionMetastatic Gastric CancerAdvanced Unresectable Gastric Cancer
Interventions
DRUG

BAY 43-9006

Given orally

DRUG

docetaxel

Given IV

DRUG

cisplatin

Given IV

Trial Locations (1)

02215

Eastern Cooperative Oncology Group, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00253370 - Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer | Biotech Hunter | Biotech Hunter